Unknown

Dataset Information

0

Extending foldamer design beyond ?-helix mimicry: ?/?-peptide inhibitors of vascular endothelial growth factor signaling.


ABSTRACT: Diverse strategies have been explored to mimic the surface displayed by an ?-helical segment of a protein, with the goal of creating inhibitors of helix-mediated protein-protein interactions. Many recognition surfaces on proteins, however, are topologically more complex and less regular than a single ?-helix. We describe efforts to develop peptidic foldamers that bind to the irregular receptor-recognition surface of vascular endothelial growth factor (VEGF). Our approach begins with a 19-residue ?-peptide previously reported by Fairbrother et al. (Biochemistry 1998, 37, 17754) to bind to this surface on VEGF. Systematic evaluation of ??? replacements throughout this 19-mer sequence enabled us to identify homologues that contain up to ~30% ? residues, retain significant affinity for VEGF, and display substantial resistance to proteolysis. These ?/?-peptides can block VEGF-stimulated proliferation of human umbilical vein endothelial cells.

SUBMITTER: Haase HS 

PROVIDER: S-EPMC3551614 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Extending foldamer design beyond α-helix mimicry: α/β-peptide inhibitors of vascular endothelial growth factor signaling.

Haase Holly S HS   Peterson-Kaufman Kimberly J KJ   Lan Levengood Sheeny K SK   Checco James W JW   Murphy William L WL   Gellman Samuel H SH  

Journal of the American Chemical Society 20120501 18


Diverse strategies have been explored to mimic the surface displayed by an α-helical segment of a protein, with the goal of creating inhibitors of helix-mediated protein-protein interactions. Many recognition surfaces on proteins, however, are topologically more complex and less regular than a single α-helix. We describe efforts to develop peptidic foldamers that bind to the irregular receptor-recognition surface of vascular endothelial growth factor (VEGF). Our approach begins with a 19-residue  ...[more]

Similar Datasets

| S-EPMC3377471 | biostudies-literature
| S-EPMC3928965 | biostudies-literature
| S-EPMC4687740 | biostudies-literature
| S-EPMC7839445 | biostudies-literature
| S-EPMC3079439 | biostudies-literature
| S-EPMC10952276 | biostudies-literature
| S-EPMC3141811 | biostudies-literature
| S-EPMC2695042 | biostudies-literature
| S-EPMC3815612 | biostudies-literature
| S-EPMC443547 | biostudies-literature